NTGN - ネオン・セラピュ―ティクス (Neon Therapeutics Inc.) ネオン・セラピュ―ティクス

 NTGNのチャート


 NTGNの企業情報

symbol NTGN
会社名 Neon Therapeutics Inc (ネオン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.  ネオン・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がんに対する免疫療法の開発に従事し、がんのネオ抗原標的療法に焦点を当てる。同社は転移性メラノ―マ、非小細胞肺がん、膀胱がんの治療用ニボルマブと組み合わせたネオ抗原ワクチンNEO-PV-01を開発する。固形がん、乳がんの治療ワクチンも手がける。本社所在地はマサチュ―セッツ州ケンブリッジ。   
本社所在地 40 Erie St. Suite 110 Cambridge MA 02139 USA
代表者氏名 Cary G. Pfeffer ケーリー・G・フェフェール
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-337-4701
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 84人
url www.neontherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/ntgn
adr_tso
EBITDA EBITDA(百万ドル) -63.43200
終値(lastsale) 10.06
時価総額(marketcap) 284724900.44
時価総額 時価総額(百万ドル) 280.76250
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 142.12950
当期純利益 当期純利益(百万ドル) -75.67200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neon Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 74% to $41.8M. Higher net loss reflects Research and development increase of 88% to $25.8M (expense) General and administrative increase of 66% to $7M (expense) Stock-based Compensation in R&D increase from $1.1M to $2.2M (expense).

 NTGNのテクニカル分析


 NTGNのニュース

   IPO Update: Hookipa Pharma Readies $100 Million IPO  2019-04-08
Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can…
   IPO Update: Hookipa Pharma Readies $100 Million IPO  2019-04-08
Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ネオン・セラピュ―ティクス NTGN Neon Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)